Risk Factors for Neuroleptic-Induced Movement Disorders

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders ed. 3. Washington, DC 1980
   Google Scholar
• Ban T. A. Drug treatment in schizophrenia. Canadian Psychiatric Association Journal 1971; 16: 473–485
   PubMedGoogle Scholar
• Barbeau A., Porcher E. New data on the genetics of Parkinson's disease. Canadian Journal of Neurological Sciences 1982; 9: 53–66
   PubMed Web of Science ®Google Scholar
• Barnes T. R., Ross M., Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals. Journal of Neurology, Neurosurgery and Psychiatry 1983; 46: 540–546
   PubMed Web of Science ®Google Scholar
• Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. Journal of the Neurological Sciences 1973; 20: 415–455
   PubMed Web of Science ®Google Scholar
• Borit A., Rubinstein L. J., Urich H. The striato-nigral degenerations: putaminal pigments and nosology. Brain 1975; 98: 101–112
   PubMed Web of Science ®Google Scholar
• Casey D. Tardive dyskinesia. Psycho-pharmacology: The Third Generation of Progress, H. Y. Meltzer. Raven Press, New York 1987; 1411–1419
   Google Scholar
• Crane G. E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
   PubMedGoogle Scholar
• DeFraites E. G., Davis K. L., Berger P. A. Coexisting tardive dyskinesia and parkinsonism. Biological Psychiatry 1977; 12: 267–272
   PubMed Web of Science ®Google Scholar
• Fann W. E., Lake C. R. The coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System 1974; 35: 324–326
   PubMedGoogle Scholar
• Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
   PubMedGoogle Scholar
• Granacher R. P. Differential diagnosis of tardive dyskinesia: An overview. American Journal of Psychiatry 1981; 138: 1288–1297
   PubMed Web of Science ®Google Scholar
• Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
   PubMed Web of Science ®Google Scholar
• Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Journal of Neurology, Neurosurgery and Psychiatry 1989; 19: 121–128
   Google Scholar
• Guttman M., Seeman P. Dopamine D2 receptor density in parkinsonian brain is consonant for duration of disease, age, and duration of L-dopa therapy. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 51–57
   Google Scholar
• Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Parkinsonism induced by dopaminergic antagonism. Advances in Neurology, D. B. Calne, T. N. Chase, A. Barbeau. Raven Press, New York 1975; vol. 9: 155–164
   Google Scholar
• Hyttel J., Larsen J. J., Christensen A. V., Arnt J. Receptor-binding profiles of neuroleptics. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 9–18
   Google Scholar
• Kanazawa I. Clinical pathophysiology of basal ganglia disease. Handbook of Neurology: Extrapyramidal Disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier, Amsterdam 1986; vol. 5: 65–85
   Google Scholar
• Kidger T., Barnes T. R. E., Trauer T., Taylor P. J. Subsyndromes of tardive dyskinesia. Psychological Medicine 1980; 10: 513–520
   PubMed Web of Science ®Google Scholar
• Klawans H. L., Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry 1974; 27: 941–947
   Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Martin J. P. The Basal Ganglia and Posture. Pitman, London 1967
   Google Scholar
• McKenna P. J. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. British Journal of Psychiatry 1987; 151: 288–301
   PubMed Web of Science ®Google Scholar
• Pisa M. Regional specialization of motor functions in the rat striatum: Implications for the treatment of parkinsonism. Progress in Neuropsychopharmacology & Biological Psychiatry 1988; 12: 217–224
   PubMed Web of Science ®Google Scholar
• Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
   PubMedGoogle Scholar
• Richardson M. A., Craig T. L. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Rosengarten H., Schweitzer J. W., Friedhoff A. J. Induction of oral dyskinesias in naive rats by D, stimulation. Life Sciences 1983; 33: 2479–2482
   PubMed Web of Science ®Google Scholar
• Roy M., Boyer L., Barbeau A. A prospective study of 50 cases of familial Parkinson's disease. Canadian Journal of Neurological Sciences 1983; 10: 37–42
   PubMed Web of Science ®Google Scholar
• Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–1133
   PubMed Web of Science ®Google Scholar
• Schooler N. R., Kane J. M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Seeman P. Brain dopamine receptors in schizophrenia and tardive dyskinesia. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 3–8
   Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
   Google Scholar
• Simpson G., Lee J., Zoubok B., Cole J. O., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
   PubMed Web of Science ®Google Scholar
• Sorokin J. E., Giordani B., Mohs R. C, Losonczy M. F., Davidson M., Siever L. J., Ryan T. A., Davis K. L. Memory impairment in schizophrenic patients with tardive dyskinesia. Biological Psychiatry 1988; 23: 129–135
   PubMed Web of Science ®Google Scholar
• Wagner H. N. Imaging D2 dopamine receptor in Parkinson's disease: A preliminary report. Recent developments in Parkinson's disease, S. Fahn, C. D. Marsden, P. Jenner, P. Teychenne. Raven Press, New York 1986; 115–118
   Google Scholar
• Wojcik J. D., Gelenberg A. J., LaBrie R. A. Prevalence of tardive dyskinesia in an outpatient population. Comprehensive Psychiatry 1980; 21: 370–380
   PubMed Web of Science ®Google Scholar
• Zetusky W. J., Jankovic J., Pirrozzolo F. J. The heterogeneity of Parkinson's disease: Clinical and prognostic implications. Neurology 1985; 35: 522–526
   PubMed Web of Science ®Google Scholar
• Aldegunde M., Miquez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders3rd ed. APA, Washington, DC 1980
   Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Bitton V., Melamed E. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Journal of Clinical Psychiatry 1984; 45: 28–30
   PubMed Web of Science ®Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the midbrain can regulate forebrain dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wain-Wright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Casey D. Tardive dyskinesia. Psychopharmacology: The third generation of progress, H. Y. Meltzer. Raven Press, New York 1987; 1411–1419
   Google Scholar
• Cotzias G. C, Tang L. C, Miller S. T., Ginos J. Z. Melatonin and abnormal movements induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Crane G. E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
   PubMedGoogle Scholar
• Datta P. G., King M. Melatonin effects on brain and behavior. Neuroscience & Biobehav-ioral Reviews 1980; 4: 451–458
   PubMed Web of Science ®Google Scholar
• DeFraites E. G., Davis K. L., Berger P. A. Coexisting tardive dyskinesia and parkinsonism. Biological Psychiatry 1977; 12: 267–272
   PubMed Web of Science ®Google Scholar
• Dubocovich M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782–784
   PubMed Web of Science ®Google Scholar
• Fahn S., Mayeux R. Unilateral Parkinson's disease and contralateral tardive dyskinesia: A unique case with successful therapy that may explain the pathophysiology of these two disorders. Journal of Neural Transmission 1980; 16: 179–185, (suppl)
   Google Scholar
• Fanget F., Claustrat B., Dalery J., Brun J., Terra J. L., Marie-Cardine M., Guyotat J. Nocturnal plasma melatonin levels in schizophrenic patients. Biological Psychiatry 1989; 25: 499–501
   PubMed Web of Science ®Google Scholar
• Fann W. E., Lake C. R. The coexistence of parkinsonism and tardive dyskinesia. Diseases of the Nervous System 1974; 35: 324–326
   PubMedGoogle Scholar
• Ferrier I. N., Arendt J., Johnstone E. C., Crow T. J. Reduced nocturnal melatonin secretion in chronic schizophrenia: Relationship to body weight. Clinical Endocrinology 1982; 17: 181–187
   PubMed Web of Science ®Google Scholar
• Fujiwara M., Inagaki C, Miwa S., Takaori S., Saeki Y., Nozaki M. Diurnal variation of dopamine content in the rat pineal gland. Life Sciences 1980; 26: 71–78
   PubMed Web of Science ®Google Scholar
• Gerlach J. Pathophysiological mechanisms underlying tardive dyskinesia. Dyskinesias: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 98–103
   Google Scholar
• Godwin-Austen R. B., Lee P. N., Marmot M. G., Stern G. M. Smoking and Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 577–581
   PubMed Web of Science ®Google Scholar
• Granacher R. P. Differential diagnosis of tardive dyskinesia: An overview. American Journal of Psychiatry 1981; 138: 1288–1297
   PubMed Web of Science ®Google Scholar
• Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: Relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
   PubMed Web of Science ®Google Scholar
• Guttman M., Seeman P. Dopamine D2 receptor density in parkinsonian brain is consonant for duration of disease, age, and duration of L-dopa therapy. Advances in neurology, M. D. Yahr, K. I. Bergmann. Raven Press, New York 1986; vol. 45: 51–57
   Google Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Kanofsky J. D., Sandyk R., Kay S. R. Edentulousness as a risk factor for tardive dyskinesia. Neurology 1990; 40: 146, (suppl)
   Google Scholar
• Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Koller W. C., Wong G. F., Lang A. Posttraumatic movement disorders: A review. Movement Disorders 1989; 4: 20–36
   PubMed Web of Science ®Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Lewinski A., Vaughan M. K., Champney T. H., Reiter R. J., Smith N. K. R. Dark exposure increases the number of pineal concretions in male gerbils (Meriones Unguiculatus). IRCS Medical Science 1983; 11: 977–978
   Google Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Miline R. The role of the pineal gland in stress. Journal of Neural Transmission 1980; 47: 191–200
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A., McCalley-Whitters M., Jacoby C. G. Cortical atrophy in schizophrenia and mania: a comparative CT study. Journal of Clinical Psychiatry 1982; 43: 439–441
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). Department of Health, Education, and Welfare, Washington, DC 1974
   Google Scholar
• Niles L. P., Wong Y. W., Mishra R. K., Brown G. M. Melatonin receptors in the brain. European Journal of Pharmacology 1979; 55: 219–220
   PubMed Web of Science ®Google Scholar
• Reiter R. J., Welsh M. G., Vaughan M. K. Age-related changes in the intact and sympathetically denervated gerbil pineal gland. American Journal of Anatomy 1976; 146: 427–432
   PubMedGoogle Scholar
• Richardson M. A., Craig T. L. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Rieder R. O., Mann L. S., Weinberger D. R., vanKammen D. P., Post R. M. Computed tomographic scans in patients with schizophrenia, schizoaffective, and bipolar affective disorder. Archives of General Psychiatry 1983; 41: 602–606
   Google Scholar
• Rosengarten H., Schweitzer J. W., Friedhoff A. J. Induction of oral dyskinesias in naive rats by D, stimulation. Life Sciences 1983; 33: 2479–2482
   PubMed Web of Science ®Google Scholar
• Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
   PubMed Web of Science ®Google Scholar
• Sandyk R., Awerbuch G. I., Kay S. R., Kanofsky J. D. Pineal calcification: Marker of tardive dyskinesia. Proceedings and Abstracts of the 143rd Annual Meeting of the American Psychiatric Association, New York, May, 1990; 12–17
   Google Scholar
• Sandyk R., Fisher H. The protective role of the pineal gland in tardive dyskinesia. International Journal of Neuroscience 1989a; 43: 215–218
   Web of Science ®Google Scholar
• Sandyk R., Fisher H. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia. Journal of Clinical Psyehopharmacology 1989b; 9: 147–148
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989c; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Sandyk R., Kay S. R. Tardive dyskinesia is associated with positive schizophrenia. International Journal of Neuroscience, (in pressa)
   Google Scholar
• Sandyk R., Kay S. R. Negative schizophrenia and the coexistence of parkinsonism and tardive dyskinesia. International Journal of Neuroscience, (in press b)
   Google Scholar
• Sandyk R., Kay S. R. Persistent tardive dyskinesia is associated with pineal gland calcification. International Journal of Neuroscience, (in press c)
   Google Scholar
• Sandyk R., Kay S. R. Effects of cigarette smoking on cognitive functions and parkinsonism in chronic schizophrenia. Neurology 1990; 40: 424, (suppl)
   Google Scholar
• Sandyk R., Mukherjee S. Attenuation of reserpine induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience 1989; 48: 297–301
   PubMed Web of Science ®Google Scholar
• Schooler N. R., Kane J. M. Research diagnoses of tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Seeman P. Brain dopamine receptors in schizophrenia and tardive dyskinesia. Dyskinesia: Research and Treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 3–8
   Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
   Google Scholar
• Trentini G. P., De Gaetani C. F., Criscuolo M., Migaldi M., Ferrari G. Pineal calcifications in different physiopathological conditions in humans. Fundamentals and clinics in pineal research, G. P. Trentini, C. DeGaetani, P. Pevet. Raven Press, New York 1987; 291–304
   Google Scholar
• Vaughan M. K., Spanel-Borowski K., Karasek M., Champney T. H., Reiter R. J. Action of subcutaneous implants or injections of melatonin on reproductive and metabolic variables and pineal concretions in male gerbils (Meriones unguiculatus). Biomedical Research 1983; 4: 329–336
   Google Scholar
• Weinberger D. R. Computed tomography (CT) findings in schizophrenia: Speculations on the meaning of it all. Journal of Psychiatric Research 1984; 18: 477–490
   PubMed Web of Science ®Google Scholar
• Welsh M. G. Pineal calcification: Structural and functional aspects. Pineal Research Reviews 1985; 3: 41–68
   Google Scholar
• Wendel O. T., Waterburg L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
   PubMedGoogle Scholar
• Yassa R., Lai S., Korpassy A., Ally J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 1987; 22: 67–72
   PubMedGoogle Scholar
• Yassa R., Mair V. The association of tardive dyskinesia and pseudoparkinsonism. Progress in Neuropsychopharmacology and Biological Psychiatry 1988; 12: 909–914
   PubMed Web of Science ®Google Scholar
• Zisapel N., Laudon M. Dopamine release induced by electrical field stimulation of rat hypothalamus in vitro inhibition by melatonin. Biochemistry, Biophysics Research Communications 1982; 104: 1610–1616
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, ed. 3. Washington, DC 1980
   Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effect of melatonin upon human brain: Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Barbeau A., Pourcher E. Genetics of early onset Parkinson's disease. Current concepts of Parkinson disease and related disorders, M. D. Yahr. Excerpta Medica, Amsterdam 1983
   Google Scholar
• Barbeau A. Experience clinique avec le tolbutamide dans la maladie de Parkinson. Union Medicate Cannada 1961; 90: 147–151
   PubMedGoogle Scholar
• Bitton V., Melamed E. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Journal of Clinical Psychiatry 1984; 45: 28–30
   PubMed Web of Science ®Google Scholar
• Boyd A. E., Lebovitz H. E., Feldman J. M. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-dopa. Journal of Clinical Endocrinology and Metabolism 1971; 33: 829–837
   PubMed Web of Science ®Google Scholar
• Brambilla F., Guastalla A., Guerrini A. Glucose-insulin metabolism in chronic schizophrenia. Diseases of the Nervous System 1976; 37: 98–103
   PubMedGoogle Scholar
• Broderick P. A., Jacoby J. H. Serotonergic function in diabetic rats: Psychotherapeutic implications. Biological Psychiatry 1988; 24: 234–239
   PubMed Web of Science ®Google Scholar
• Butterworth R. F., Belanger F., Barbeau A. Hypokinesia produced by antero-lateral hypothalamic 6-hydroxydopamine lesions and its reversal by some antiparkinson drugs. Pharmacology, Biochemistry & Behavior 1977; 8: 41–45
   Web of Science ®Google Scholar
• Chase T. N. Serotonergic mechanisms in Parkinson's disease. Archives of Neurology 1972; 27: 354–356
   PubMedGoogle Scholar
• Cotzias G. C, VanWoert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine 1967; 276: 314–319
   PubMed Web of Science ®Google Scholar
• Datta P. C., King M. G. Melatonin: Effects on brain and behavior. Neuroscience and Bio-behavioral Reviews 1978; 4: 451–458
   Web of Science ®Google Scholar
• Gates E. W., Hyman I. Use of tolbutamide in paralysis agitans: preliminary report. Journal of the American Medical Association 1960; 172: 1351–1354
   PubMed Web of Science ®Google Scholar
• Hansen J. M., Kristensen M. Tolbutamide in the treatment of Parkinson's disease. A double blind trial. Danish Medical Bulletin 1965; 2: 181–184
   Google Scholar
• Hassan M. M., Bottoms S. F., Evans M. I. Fetal-alpha-melanocyte-stimulating hormone levels: no correlation with the late fetal growth but increased with diabetes mellitus. American Journal of Obstetrics and Gynecology 1986; 154: 428–430
   PubMed Web of Science ®Google Scholar
• Jacquet Y. F., Abrams G. M. Postural asymmetry and movement disorder after unilateral microinjection of adrenocorticotropin 1–24 in rat brainstem. Science 1982; 218: 175–177
   PubMed Web of Science ®Google Scholar
• Lang A. E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37: 477–481
   PubMed Web of Science ®Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Diseases 1974; 27: 573–579
   PubMedGoogle Scholar
• Lozovsky D., Sailer C. F., Kopin I. J. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031–1033
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Bilder R. M., Sackeim H. L. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
   Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal involuntary movement scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
   Google Scholar
• Pang S. F., Tang F., Tang P. L. Alloxan-induced diabetes and the pineal gland: Differential effects on the levels of pineal N-acetylserotonin, pineal melatonin, and serum melatonin. Journal of Pineal Research 1985; 2: 79–85
   PubMed Web of Science ®Google Scholar
• Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton I. P. Pro-opiomelanocortin peptides in the human hypothalamus: Comparative studies between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Podolsky S., Leopold N. A., Sax D. S. Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1972; 1: 1356–1359
   PubMed Web of Science ®Google Scholar
• Rainero I., Kaye J. A., May C, Durso R., Katz D. I., Albert M. L., Wolfe N., Pinessi L., Friedland R. P., Rapoport S. I. Alpha-melanocyte stimulating hormonelike immuno-reactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Archives of Neurology 1988; 45: 1224–1227
   PubMedGoogle Scholar
• Richardson M. A., Craig T. J. The coexistence of Parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Sailer C. F., Chiodo L. A. Glucose suppresses basal firing and haloperidol-induced increases in firing rate of central dopaminergic neurons. Science 1980; 210: 1269–1271
   PubMed Web of Science ®Google Scholar
• Sandyk R. The effects of dopamine hydrochloride on insulin action in isolated rat adipocytes. M.Sc. Dissertation, University of the Witwatersrand, JohannesburgSouth Africa 1984
   Google Scholar
• Singh S., Sandyk R., Kay S. R. Diabetes mellitus as a risk factor for neuroleptic-induced akathisia. Neurology 1990; 40: 146, (suppl)
   Google Scholar
• Szabo A. J., Szabo O. Influence of the insulin sensitive CNS regulator receptor on hepatic glucose metabolism. Journal of Physiology 1975; 253: 121–133
   PubMed Web of Science ®Google Scholar
• Szabo O., Szabo A. J. Effects of autonomic neurotransmitter and inhibitor drugs on the insulin sensitive CNS glucoregulatory center. Diabetes 1974; 23: 342
   Web of Science ®Google Scholar
• Tolosa E. S., Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984; 34: 1516–1518
   PubMed Web of Science ®Google Scholar
• VanWoert M. H., Mueller P. S. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clinical Pharmacology & Therapeutics 1971; 12: 360–367
   PubMed Web of Science ®Google Scholar
• Wilkinson D. G. Psychiatric aspects of diabetes mellitus. British Journal of Psychiatry 1981; 138: 1–9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
   Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
   PubMedGoogle Scholar
• Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
   PubMed Web of Science ®Google Scholar
• Hausner R. S. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment. Journal of Clinical Psychiatry 1983; 44: 13–16
   PubMed Web of Science ®Google Scholar
• Johnson D. A. W. Prevalence and treatment of drug-induced extrapyramidal symptoms. British Journal of Psychiatry 1978; 132: 27–30
   Web of Science ®Google Scholar
• Korczyn A. D., Inzelberg R., Treves T., Neufeld M., Reider I., Rabey P. M. Dementia of Parkinson's disease. Advances in Neurology, M. D. Yahr, K. J. Bergmann. Raven Press, New York 1986; vol. 45: 399–403
   Google Scholar
• Langston J. W., Forno L. S. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
   PubMed Web of Science ®Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Disease 1974; 27: 537–579
   PubMedGoogle Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Mindham R. H. S., Ahmed S. W. A., Clough C. G. A controlled study of dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 969–974
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Bilder R. M., Sackheim H. A. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
   Web of Science ®Google Scholar
• Mutch W. J., Dingwall-Fordyce I., Downie A. W., Paterson J. G., Roy S. K. Parkinson's disease in a Scottish city. British Medical Journal 1986; 292: 534–536
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal Involuntary Movement Scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
   Google Scholar
• Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
   PubMedGoogle Scholar
• Stephen P. J., Williamson J. Drug-induced Parkinsonism in the elderly. Lancet 1984; 2: 1082–1083
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenic: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
   PubMed Web of Science ®Google Scholar
• Wilkinson D. G. Psychiatric aspects of diabetes mellitus. British Journal of Psychiatry 1981; 138: 1–9
   PubMed Web of Science ®Google Scholar
• Yaryura-Tobias J. A., Wolpert A., Dana L., Merlis S. Action of L-dopa in drug induced extrapyramidalism. Diseases of the nervous system 1970; 31: 60–63
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
   Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Braude W. M., Barnes T. R. E. Late onset akathisia–an indicant of covert dyskinesia: two case reports. American Journal of Psychiatry 1983; 140: 611–612
   PubMed Web of Science ®Google Scholar
• Gibb W. R. G., Lees A. J. The clinical phenomenon of akathisia. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 861–866
   PubMed Web of Science ®Google Scholar
• Karam J. H. Diabetes mellitus, hypoglycemia and lipoprotein disorders. Current medical diagnosis & treatment, S. A. Schroeder, M. A. Krupp, L. M. Tierney, S. J. McPhee. Appleton & Lange, Nor-walk 1989; 789
   Google Scholar
• Klawans H. L. The pharmacology of tardive dyskinesia. American Journal of Psychiatry 1973; 130: 82–86
   PubMed Web of Science ®Google Scholar
• Lackovic Z., Salkovic M., Kuqi Z., Relja M. Dopamine, norepinephrine and serotonin in the brain of diabetic rat and man. Journal of Neurochemistry 1985; 44: S94, (suppl)
   PubMedGoogle Scholar
• Lees A. J. Tics and related disorders. Churchill-Livinstone, Edinburgh 1985
   Google Scholar
• Lozovsky D., Sailer C. F., Kopin I. J. Dopamine receptor binding is increased in diabetic rats. Science 1981; 214: 1031–1033
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Bilder R. M., Sackheim H. A. Tardive dyskinesia and glucose metabolism. Archives of General Psychiatry 1986; 43: 193
   Web of Science ®Google Scholar
• Mukherjee S., Roth S. D., Sandyk R., Schnur D. B. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance. Psychiatry Research 1989; 29: 17–27
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Abnormal Involuntary Movement Scale. Department of Health, Education, and Welfare, Alcohol, Drug Abuse and Mental Health Administration, Washington, DC 1964
   Google Scholar
• Sailer C. F., Chiodo L. A. Glucose suppresses basla firing and haloperidol-induced increases in firing rate of central dopaminergic neurons. Science 1980; 210: 1269–1271
   PubMed Web of Science ®Google Scholar
• Sandyk R. Increased incidence of neuroleptic-induced perioral movements in the rat by hyperglycemia. International Journal of Neuroscience 1990; 50: 227–232
   PubMed Web of Science ®Google Scholar
• VanPutten T., May P., Marder S. R. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 1984; 41: 1036–1039
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
   Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Cash R., Dennis T., L'Heureux R., Raisman R., Javoy-Agid F., Scatton B. Parkinson's disease and dementia: Norepinephrine and dopamine in locus coeruleus. Neurology 1987; 37: 42–46
   PubMed Web of Science ®Google Scholar
• Davis J. M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33: 858–861
   PubMed Web of Science ®Google Scholar
• Famuyiwa O. O., Eccleston D., Donaldson A. A., Garside R. F. Tardive dyskinesia and dementia. British Journal of Psychiatry 1979; 135: 500–504
   PubMed Web of Science ®Google Scholar
• Goetz C. G. Drug-induced parkinsonism and idiopathic Parkinson's disease. Archives of Neurology 1983; 40: 325–326
   PubMedGoogle Scholar
• Gottfries C. G., Gottfries I., Roos B. E. The investigation of homovanillic acid in human brain and its correlation to senile dementia. British Journal of Psychiatry 1969; 115: 563–574
   PubMed Web of Science ®Google Scholar
• Hardie R. J., Lees A. J. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 850–854
   PubMed Web of Science ®Google Scholar
• Hoffman W. F., Labs S., Casey D. E. Neuroleptic-induced Parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Holden J. M.C, Itil T. M., Keskiner A. The treatment of lobotomized schizophrenic patients with butaperazine. Current Therapeutic Research 1969; 11: 418–428
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. Brain neurotramsitter changes in Parkinson's disease. Movement disorders, C. D. Marsden, S. Fahn. Butterworth, Woburn Mass 1982; 41–58
   Google Scholar
• Luchins D. J., Jackman H., Meltzer H. Y. Lateral ventricular size and drug-induced parkinsonism. Psychiatry Research 1983; 9: 9–16
   PubMed Web of Science ®Google Scholar
• Mann D. M. A., Yates P. O., Hawkes J. The pathology of the human locus coeruleus. Clinical Neuropathology 1983; 2: 1–7
   PubMed Web of Science ®Google Scholar
• McLelland H. A. Discussion on assessment of drug-induced extrapyramidal reactions. British Journal of Clinical Pharmacology 1976; 401–403, suppl
   PubMed Web of Science ®Google Scholar
• Mindham R. H. S. Assessment of drug-induced extrapyramidal reactions and of drugs given for their control. British Journal of Clinical Pharmacology 1976; 395–400, suppl
   PubMed Web of Science ®Google Scholar
• Molsa P. K., Marttila R. J., Rinne U. K. Extrapyramidal signs in Alzheimer's disease. Neurology 1984; 34: 1114–1116
   PubMed Web of Science ®Google Scholar
• Morris J. C, Drazner M., Grant E. A., Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?. Archives of Neurology 1989; 46: 651–657
   PubMedGoogle Scholar
• Mortimer J. A., Pirozzolo F. J., Hansen E. C., Webster D. D. Relationship of motor symptoms to intellectual deficits in Parkinson's disease. Neurology 1982; 32: 133–37
   PubMed Web of Science ®Google Scholar
• Pearce J. The extrapyramidal disorder of Alzheimer's disease. European Neurology 1974; 12: 94–103
   PubMed Web of Science ®Google Scholar
• Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J., Crow T. T. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. Journal of the Neurological Sciences 1981; 51: 279–287
   PubMed Web of Science ®Google Scholar
• Rajput A. H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Archives of Neurology 1982; 39: 644–646
   PubMedGoogle Scholar
• Richardson M. A., Craig T. J. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 1982; 139: 341–343
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. The relationship of the reticular system to the primary pathoetiology of Parkinson's disease. International Journal of Neuroscience 1988; 42: 297–300
   PubMed Web of Science ®Google Scholar
• Sandyk R., Kay S. R. Coexistence of drug-induced parkinsonism and tardive dyskinesia. International Journal of Neuroscience, (in press)
   Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
   Google Scholar
• Stern Y., Mayeux R., Cote L. Reaction time and vigilance in Parkinson's disease. Possible role of altered norpeinephrine metabolism. Archives of Neurology 1984; 41: 1086–1089
   PubMedGoogle Scholar
• Sulkava R. Alzheimer's disease and senile dementia of Alzheimer's type: a comparative study. Acta Neurologica Scandinavica 1982; 65: 636–650
   PubMed Web of Science ®Google Scholar
• Waddington J. L., Youssef H. A. An unusual cluster of tardive dyskinesia in schizophrenic: Association with cognitive dysfunction and negative symptoms. American Journal of Psychiatry 1986; 143: 1162–1165
   PubMed Web of Science ®Google Scholar
• Winblad B., Adolfsson R., Carlsson A. Biogenic amines in brains of patients with Alzheimer's disease. Alzheimer's disease: A report of progress in research, S. Corkin, K. L. Davis, J. H. Crowdon. Raven Press, New York 1982; 25–33
   Google Scholar
• Youssef H. A., Waddington J. L. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dyskinesia. Biological Psychiatry 1988; 23: 791–796
   PubMed Web of Science ®Google Scholar
• Zetusky W. J., Jankovic J., Pirozzolo F. J. The heterogeneity of Parkinson's disease: Clinical and prognotic implications. Neurology 1985; 35: 522–526
   PubMed Web of Science ®Google Scholar
• Adler L. A., Angrist B., Reiter S., Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 97: 1–11
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. A psychiatric glossary 5th ed. APA, Washington, DC 1980a
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980b
   Google Scholar
• Asberg M., Traskman L., Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor?. Archives of General Psychiatry 1976; 33: 1193–1197
   PubMed Web of Science ®Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Bing R. Ueber einige Bemerkenswerte Begleiterscheinungen der extrapyramidalen Rigiditat (Akathesie-Mikrographie-Kinesia paradoxica). Schweizerische Medizinische Wochenschrift 1923; 53: 167–171
   Google Scholar
• Braude W. M., Barnes T. R. E., Gore S. M. Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. British Journal of Psychiatry 1983; 143: 139–150
   PubMed Web of Science ®Google Scholar
• Curzon G. Serotonergic mechanisms in depression. Clinical Neuropharmacology 1988; 11: S11–S20, (suppl 2)
   PubMed Web of Science ®Google Scholar
• Drake R. E., Ehrlich J. Suicide attempts associated with akathisia. American Journal of Psychiatry 1985; 142: 499–501
   PubMed Web of Science ®Google Scholar
• Gibb W. R. G., Lees A. J. The clinical phenomenon of akathisia. Journal of Neurology, Neurosurgery and Psychiatry 1986; 49: 861–866
   PubMed Web of Science ®Google Scholar
• Haskovec L. Nouvelles remarques sur ľakathisie. Nouvelle Iconograph Salpetriere 1903; 16: 287–296
   Google Scholar
• Kalinowsky L. B. Appraisal of the “tranquilizers” and their influence on other somatic treatments in psychiatry. American Journal of Psychiatry 1958; 115: 294–300
   PubMed Web of Science ®Google Scholar
• Keckich W. A. Neuroleptic: Violence as a manifestation of akathisia. Journal of the American Medical Association 1978; 240: 2185
   Web of Science ®Google Scholar
• Kendler K. S. A medical student's experience with akathisia. American Journal of Psychiatry 1976; 133: 454–455
   Web of Science ®Google Scholar
• Lang A. E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37: 411–481
   Web of Science ®Google Scholar
• Lees A. J. Tics and related disorders. Churchill-Livingstone, Edinburgh 1985
   Google Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapryamidal side effects of neuroleptic drugs. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Muehlbauer H. D. Human aggression and the role of central serotonin. Pharmacopsychiatrie 1985; 18: 218–221
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Rosen A. M., Cardenas C, Varia V., Olarte S. Tardive dyskinesia in psychiatric outpatients. Archives of General Psychiatry 1982; 39: 466–469
   PubMed Web of Science ®Google Scholar
• Ninan P. T., vanKammen D. P., Scheinin M., Linnoila M., Bunney W. E., Goodwin F. K. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry 1984; 141: 566–569
   PubMed Web of Science ®Google Scholar
• Roy A., DeJong J., Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow-up study. Archives of General Psychiatry 1989; 46: 609–612
   PubMed Web of Science ®Google Scholar
• Sandyk R. Neuroleptic-induced akathisia: A role for MSH peptides. Psychopharmacology 1989; 99: 134–135
   PubMed Web of Science ®Google Scholar
• Shaw E. D., Mann J. J., Widen P., Sinsheimer L. M., Brunn R. D. A case of suicidal and homicidal ideation aned akathisia in a double-blind neuroleptic crossover study. Journal of Psychopharmacology 1986; 6: 196–197
   Web of Science ®Google Scholar
• Shen W. W. Akathisia: An overlooked, distressing, but treatable condition. The Journal of Nervous and Mental Disease 1981; 169: 599–600
   PubMed Web of Science ®Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
   Google Scholar
• Stewart J. Akathisia following traumatic brain injury: treatment with bromocriptine. Journal of Neurology, Neurosurgery and Psychiatry 1989; 52: 1200–1201
   PubMed Web of Science ®Google Scholar
• vanPraag H. M. Neurotransmitters and CNS disease: Depression. Lancet 1982; 2: 1259–1264
   PubMedGoogle Scholar
• vanPraag H. M. CSF-5HIAA and suicide in non-depressed schizophrenics. Lancet 1983; 1: 977–978
   PubMedGoogle Scholar
• vanPutten T. Why do schizophrenic patients refuse to take their drugs?. Archives of General Psychiatry 1974; 31: 67–72
   PubMed Web of Science ®Google Scholar
• vanPutten T. The many faces of akathisia. Comprehensive Psychiatry 1975; 16: 43–47
   PubMed Web of Science ®Google Scholar
• vanPutten T., May P., Marder S. R. Akathisia with haloperidol and thiothixene. Archives of General Psychiatry 1984; 41: 1036–1039
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders ed. 3. Washington, DC 1980
   Google Scholar
• Ayd F. J. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175: 1054–1060
   PubMed Web of Science ®Google Scholar
• Ban T. A. Drug treatment in schizophrenia. Canadian Psychiatric Association Journal 1971; 16: 473–485
   PubMedGoogle Scholar
• Donlon P. T., Stenson R. L. Neuroleptic-induced extrapyramidal symptoms. Diseases of the Nervous System 1976; 37: 629–635
   PubMedGoogle Scholar
• Hoffman W. F., Labs S. M., Casey D. E. Neuroleptic-induced parkinsonism in older schizophrenics. Biological Psychiatry 1987; 22: 427–439
   PubMed Web of Science ®Google Scholar
• Kane J. M., Woerner M., Liberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. Dyskinesia: research and treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer Verlag, Berlin 1985; 72–78
   Google Scholar
• Kane J. M., Woerner M., Lieberman J. Tardive dyskinesia: Prevalence, incidence and risk factors. Journal of Clinical Psychopharmacology 1988; 8: 52S–56S, (suppl)
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drug. Psychological Medicine 1980; 10: 55–72
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Rosen A. M., Caracci G., Shukla S. Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry 1986; 43: 342–346
   PubMed Web of Science ®Google Scholar
• Rupniak N. M. J., Jenner P., Marsden C. D. Acute dystonia induced by neuroleptic drugs. Psychopharmacology 1986; 88: 403–419
   PubMed Web of Science ®Google Scholar
• Schooler N. R., Kane J. M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Simpson G. M., Angus J. W. S. Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica 1970; 212: 1–58, (suppl)
   Google Scholar
• Youssef H. A., Waddington J. L. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: Overrepresentation in patients with tardive dykinesia. Biological Psychiatry 1988; 23: 791–796
   PubMed Web of Science ®Google Scholar
• Adams R. D., Victor M. Principles of neurology. McGraw-Hill, San Francisco 1977; 717–719
   Google Scholar
• Alcolado J. C, Moore I. E., Weller R. O. Calcifications in the human choroid plexus, menigiomas and pineal gland. Neuropathology and Applied Neurobiology 1986; 12: 235–250
   PubMed Web of Science ®Google Scholar
• Ashcroft G. W., Dow R. C, Moir A. T. B. The active transport of 5-hydroxyindoleacetic acid and 3-methoxy-4 hydroxyphenylacetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaethetized dog. Journal of Physiology 1968; 199: 397–425
   PubMedGoogle Scholar
• Campbell W. G., Raskind M. A., Gordon T., Mei Shaw C. Iron pigment in the brain of a man with tardive dyskinesia. American Journal of Psychiatry 1985; 142: 364–365
   PubMed Web of Science ®Google Scholar
• Casey D. E., Denney D. Pharmocological characterisation of tardive dyskinesia. Psycho-pharmacology 1977; 54: 1–9
   PubMed Web of Science ®Google Scholar
• Chase T. N., Schnur J. A., Gordon E. K. Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders. Neuropharmacology 1970; 9: 265–268
   PubMed Web of Science ®Google Scholar
• Decker J. F., Quay W. B. Stimulatory effects of melatonin on ependymal epithelium of choroid plexus in golden hamsters. Journal of Neural Transmission 1982; 55: 53–67
   PubMed Web of Science ®Google Scholar
• Friedheim E., Corvi C, Graziano J., Donnelli T., Breslin D. Choroid plexus as protective sink for heavy metals. Lancet 1983; 1: 981–982
   PubMed Web of Science ®Google Scholar
• Gureje O. Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1525–1530
   PubMed Web of Science ®Google Scholar
• Gureje O. The significance of subtyping tardive dyskinesia: a study of prevalence and associated factors. Psychological Medicine 1989; 19: 121–128
   PubMed Web of Science ®Google Scholar
• Hunter R., Blackwood W., Smith M. C. Neuropatholgical findings in three cases of persistent dyskinesia following phenothiazine medication. Journal of the Neurological Sciences 1968; 7: 763–773
   Web of Science ®Google Scholar
• Kidger T., Barnes T. R. E., Trauer T., Taylor P. J. Subsyndromes of tardive dyskinesia. Psychological Medicine 1980; 10: 513–520
   PubMed Web of Science ®Google Scholar
• Korsgaard O., Gerlach J., Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European Journal of Pharmacology 1985; 118: 245–252
   PubMed Web of Science ®Google Scholar
• Lidvall M., Owman C. Autonomic nerves in the mammalian choroid plexus and their influence on the formation of cerebrospinal fluid. Journal of Cerebral Blood Flow and Metabolism 1981; 1: 245–266
   PubMed Web of Science ®Google Scholar
• MacPherson P., Matheson M. S. Comparison of calcification of pineal, habenular commisure and choroid plexus on plain films and computed tomography. Neuroradiology 1979; 18: 67–72
   PubMed Web of Science ®Google Scholar
• Manton W. I., Kirkpatrick J. B., Cook J. D. Does the choroid plexus really protect the brain from lead?. Lancet 1984; 2: 351
   PubMed Web of Science ®Google Scholar
• Maurizi C. P. The pathophysiology of enlarged ventricles in normal pressure communicating hydrocephalus and schizophrenia: A possible therapeutic role for melatonin. Medical Hypotheses 1987; 23: 61–66
   PubMed Web of Science ®Google Scholar
• Modic M. T., Weinstein M. A., Rothner D., Evenberg G., Duchesneau P. M., Kaufman B. Calcification of the choroid plexus visualized by computed tomography. Neuroradiology 1980; 135: 369–372
   Google Scholar
• Moskowitz M. A., Liebmann J. E., Reinhard J. F., Schlosberg A. Raphe origin of serotonin-containing neurons within the choroid plexus of the rat. Brain Research 1979; 169: 590–594
   PubMed Web of Science ®Google Scholar
• Owens D. G.C, Johnstone E. C, Crow T. J., Frith C. D., Jagoe J. R., Kreel L. Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychological Medicine 1985; 15: 27–41
   PubMed Web of Science ®Google Scholar
• Pfefferbaum A., Zipursky R. B., Lim K. O., Zatz L. M., Stahl S. M., Jernigan T. L. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry 1988; 45: 633–640
   PubMed Web of Science ®Google Scholar
• Potkin S. G., Weinberger D. R, Linnoila M., Wyatt R. J. Low CSF 5-hydroxyindoleacettic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry 1983; 140: 21–25
   PubMed Web of Science ®Google Scholar
• Rapoport S. I. Blood-brain barrier in physiology and medicine. Raven Press, New York 1976; 43–86
   Google Scholar
• Rudin D. O. Covert transport dysfunction in the choroid plexus as a possible cause of schizophrenia. Schizophrenia Bulletin 1979; 5: 623–626
   PubMed Web of Science ®Google Scholar
• Rudman D., Hollins B. M., Lewis N. C., Scott J. W. Effects of hormones on 3′5,-cyclic adenosine monophosphate in choroid plexus. American Journal of Physiology 1977; 232: 353–357
   Google Scholar
• Sandyk R., Awerbuch G. I., Kay S. R. Pineal calcification and tardive dyskinesia. Lancet 1990; 335: 1528
   PubMed Web of Science ®Google Scholar
• Simpson G., Lee J., Zoubok B., Cole J. O., Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology 1979; 64: 171–179
   PubMed Web of Science ®Google Scholar
• Smith J. M., Baldessarini R. J. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980; 37: 1368–1373
   PubMed Web of Science ®Google Scholar
• Smulders A. P., Wright E. M. Role of choroid plexus in transport of melatonin between blood and brain. Brain Research 1980; 191: 555–558
   PubMed Web of Science ®Google Scholar
• Tapp E. The histology and pathology of the human pineal gland. Progress in Brain Research 1979; 52: 481–500
   PubMedGoogle Scholar
• Zimmerman R. A., Bilaniuk L. T. Age-related incidence of pineal calcification detected by computed tomography. Neuroradiology 1982; 142: 659–662
   Google Scholar